CRESCENT BIOPHARMA, INC. Cash and Restricted Cash
CRESCENT BIOPHARMA, INC. (CBIO) had Cash and Restricted Cash of $171.70 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-30
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $171.70M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $189.27M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $213.30M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $133.37M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $171.70M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $189.27M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $213.30M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $133.37M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $152.75M 10-Q · filed 2026-07-30 |
| 2025-03-31 | $22.43M 10-Q · filed 2026-04-29 |
| 2024-12-31 | $34.77M 10-Q · filed 2026-07-30 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 |
| 2024-09-19 | $0.00 10-K · filed 2026-02-26 |
| 2024-09-18 | $0.00 10-Q · filed 2025-11-06 |
| 2022-03-31 | $76.52M 10-Q · filed 2022-04-28 |
| 2021-12-31 | $90.25M 10-Q · filed 2022-04-28 |
| 2021-09-30 | $101.92M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $118.85M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $132.47M 10-Q · filed 2022-04-28 |
| 2020-12-31 | $137.04M 10-Q · filed 2022-04-28 |
| 2020-09-30 | $142.87M 10-Q · filed 2021-11-02 |
| 2020-06-30 | $149.84M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $154.82M 10-Q · filed 2021-05-03 |
| 2019-12-31 | $158.20M 10-K · filed 2022-03-03 |
| 2019-09-30 | $170.89M 10-Q · filed 2020-11-06 |
| 2019-06-30 | $184.17M 10-Q · filed 2020-07-31 |
| 2019-03-31 | $195.56M 10-Q · filed 2020-05-01 |
| 2018-12-31 | $209.92M 10-K · filed 2022-03-03 |
| 2018-09-30 | $219.83M 10-Q · filed 2019-11-07 |
| 2018-06-30 | $229.43M 10-Q · filed 2019-08-01 |
| 2018-03-31 | $242.63M 10-Q · filed 2019-05-02 |
| 2017-12-31 | $123.92M 10-K · filed 2021-03-02 |
| 2017-09-30 | $112.87M 10-Q · filed 2018-11-02 |
| 2017-06-30 | $119.15M 10-Q · filed 2018-08-09 |
| 2016-12-31 | $40.04M 10-K · filed 2020-02-28 |
| 2015-12-31 | $46.80M 10-K · filed 2019-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |